Mar. 30 at 6:53 PM
$LEXX Relative comps for Lexaria.
Halozyme Therapeutics (
$HALO ):
$7.3 Billion. The industry leader in drug delivery. They use their ENHANZE platform to help Big Pharma turn intravenous drugs into simple subcutaneous injections.
Sounds similar to Lexaria but we are doing that orally for any peptide 👀 👆👆👆
• Provention Bio (
$PRVB):
$2.9 Billion (Acquired). Focused on intercepting and preventing immune-mediated diseases. They were acquired by Sanofi in 2023 for approximately
$2.9 billion to bolster their diabetes and immunology pipeline.
• Rani Therapeutics (
$RANI):
$111 Million. Developers of the "RaniPill," a robotic capsule intended to replace injections by delivering large molecules (like GLP-1s) directly into the intestinal wall.
